image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Media Contact:
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
Lwolffe@wheelhouselsa.com

Date Title and Summary Additional Format
July 11, 2024 Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief
PDF Version
July 8, 2024 Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T.
PDF Version
June 16, 2024 Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal trial(s) in 2025
PDF Version
June 10, 2024 Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
Webcast and call will be held at 9:00 a.m., ET (3:00 p.m., CEST), on Sunday, June 16, 2024, after the presentation at EHA2024 SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation
PDF Version
May 29, 2024 Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T.
PDF Version
May 28, 2024 Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with
PDF Version
May 20, 2024 Nurix Therapeutics Announces Board Chair Transition
David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.
PDF Version
May 14, 2024 Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations to BTK inhibitors The oral presentation at EHA will include additional data at
PDF Version
May 7, 2024 Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T.
PDF Version
April 16, 2024 Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise
PDF Version
Displaying 1 - 10 of 27
Print Page
Email Alerts
RSS Feeds
Contact IR